医疗设备制造商史赛克(Stryker)周一宣布将以49亿美元的价格收购英纳利医疗公司(Inari Medical),引发后者股价在夜盘大涨21.54%。
这一收购交易将有助于史赛克扩大其治疗静脉疾病的产品线。总部位于加利福尼亚州的英纳利医疗是一家专门从事治疗肺栓塞、深静脉血栓和支架内血栓等疾病的设备和系统制造商。此举将显著增强史赛克公司在这一细分市场的实力。
英纳利医疗公司消息人士表示,在史赛克等多方传出有意收购后,该公司最近几周一直与顾问探讨出售事宜。此前一年,在静脉疾病治疗设备需求激增的大环境下,英纳利医疗的股价逆市下跌约21%。因此,此次收购无疑为公司和股东带来了重大利好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.